CDKN2A and meningioma: The median time to meningioma progression in the heterozygous CDKN2A/B deletion arm was 26.1 (95% CI 23.3–29.0) months, whereas in those with a homozygous CDKN2A/B deletion median PFS time was 11.0 (95% CI 8.6–13.3) months (p = 0.032, see Fig. 3c).